Hematopoietic Stem Cell Transplantation in Patients with Heterozygous STAT1 Gain-of-Function Mutation
- 13 December 2018
- journal article
- research article
- Published by Springer Nature in Journal of Clinical Immunology
- Vol. 39 (1) , 37-44
Abstract
Purpose Human signal transducer and activator of transcription 1 (STAT1) gain-of-function (GOF) mutations present with a broad range of manifestations ranging from chronic mucocutaneous candidiasis and autoimmunity to combined immunodeficiency (CID). So far, there is very limited experience with hematopoietic stem cell transplantation (HSCT) as a therapeutic modality in this disorder. Here, we describe two patients with heterozygous STAT1 GOF mutations mimicking CID who were treated with HSCT. Methods Data on the HSC sources, conditioning regimen, graft-versus-host disease (GvHD) and antimicrobial prophylaxis, and the post-transplant course including engraftment, GvHD, transplant-related complications, infections, chimerism, and survival were evaluated. Pre- and post-transplant immunological studies included enumeration of circulating interferon gamma (IFN-γ)- and interleukin 17 (IL-17)-expressing CD4+ T cells and analysis of IFN-β-induced STAT1 phosphorylation in patient 1 (P1)’s T cells. Results P1 was transplanted with cord blood from an HLA-identical sibling, and P2 with bone marrow from a fully matched unrelated donor using a reduced toxicity conditioning regimen. While P1 completely recovered from her disease, P2 suffered from systemic CMV disease and secondary graft failure and died due to severe pulmonary involvement and hemorrhage. The dysregulated IFN-γ production, suppressed IL-17 response, and enhanced STAT1 phosphorylation previously found in the CD4+ T cells of P1 were normalized following transplantation. Conclusion HSCT could be an alternative and curative therapeutic option for selected STAT1 GOF mutant patients with progressive life-threatening disease unresponsive to conventional therapy. Morbidity and mortality-causing complications included secondary graft failure, infections, and bleeding.Keywords
Funding Information
- National Institutes of Health (5R01AI065617)
- Türkiye Bilimsel ve Teknolojik Araştırma Kurumu (1059B191401284)
This publication has 18 references indexed in Scilit:
- Alanine-scanning mutagenesis of human signal transducer and activator of transcription 1 to estimate loss- or gain-of-function variantsJournal of Allergy and Clinical Immunology, 2017
- Heterozygous STAT1 gain-of-function mutations underlie an unexpectedly broad clinical phenotypeBlood, 2016
- The Extended Clinical Phenotype of 26 Patients with Chronic Mucocutaneous Candidiasis due to Gain-of-Function Mutations in STAT1Journal of Clinical Immunology, 2015
- Use of ruxolitinib to successfully treat chronic mucocutaneous candidiasis caused by gain-of-function signal transducer and activator of transcription 1 (STAT1) mutationJournal of Allergy and Clinical Immunology, 2015
- RETRACTED: Continuous G-CSF therapy for isolated chronic mucocutaneous candidiasis: Complete clinical remission with restoration of IL-17 secretionJournal of Allergy and Clinical Immunology, 2013
- Molecular mechanisms of mucocutaneous immunity against Candida and Staphylococcus speciesJournal of Allergy and Clinical Immunology, 2012
- Autosomal-Dominant Chronic Mucocutaneous Candidiasis with STAT1-Mutation can be Complicated with Chronic Active Hepatitis and HypothyroidismJournal of Clinical Immunology, 2012
- Inborn Errors of Human JAKs and STATsImmunity, 2012
- STAT1Mutations in Autosomal Dominant Chronic Mucocutaneous CandidiasisNew England Journal of Medicine, 2011
- Gain-of-function human STAT1 mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasisJournal of Experimental Medicine, 2011